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Abstract
Background: Dexmedetomidine can be used for sedation of mechanically ventilated patients and has minor
respiratory effects. The aim of this study was to compare the incidence of patient-ventilator dyssynchronies during
sedation with dexmedetomidine or propofol.
Methods: We conducted a multicentre, prospective, open-label, randomised clinical trial, comparing dexmedetomidine
with standard propofol sedation at three intensive care units of university hospitals in Italy. Twenty difficult-to-wean
patients for whom the first weaning trial had failed and who were on pressure support ventilation were randomised to
receive sedation with either dexmedetomidine or propofol at a similar level of sedation (Richmond Agitation-Sedation
Scale [RASS] score +1 to −2). The asynchrony index (AI) was calculated using tracings of airflow, airway pressure and
electrical activity of the diaphragm sampled at 0, 0.5, 1, 2, 6, 12, 18 and 24 h.
Results: The mean AI was lower with dexmedetomidine than with propofol from 2 h onwards, although the two groups
significantly differed only at 12 h (2.68 % vs 9.10 %, p < 0.05). No further difference was observed at 18 and 24 h.
Conclusions: When sedation with propofol and dexmedetomidine was compared at similar RASS scores of patients in
whom first weaning trial had failed, the AI was lower with dexmedetomidine than with propofol, and this difference was
statistically significant at 12 h. These results suggest that sedation with dexmedetomidine may offer some advantages in
terms of patient-ventilator synchrony.
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Background
Patients receiving assisted mechanical ventilation (MV)
commonly require sedation to optimize tolerance to the
endotracheal tube and to better adapt to the ventilator,
thus decreasing stress response, anxiety and discomfort
[1–5]. Use of sedation to optimize the patient-ventilator
interaction can help avoid prolongation of MV and
intensive care unit (ICU) length of stay as well as an in-
creased need for tracheostomy [6, 7].
For several decades, γ-aminobutyric acid receptor ago-
nists (including propofol and benzodiazepines) have been
the most commonly used sedatives for critically ill patients,
including those receiving assisted MV [1, 4, 5, 8]. During
assisted MV, patient-ventilator interaction is influenced
both by machine settings [6, 7] and by the patient’s respira-
tory pattern, timing and drive [8, 9]. These are directly af-
fected by sedatives, whose effects vary, depending both on
the drug used and on the dose administered [10, 11]. Very
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recently, research has shown that sedation with propofol
was associated with a reduction in respiratory drive causing
significant derangements in patient-ventilator synchrony in
ICU patients receiving assisted ventilatory support [9]. As
part of that research, the electrical activity of the diaphragm
(EAdi) signal, determined using a nasogastric feeding tube
with a multiple array of electrodes placed at its distal end,
was successfully used to assess respiratory drive, neural re-
spiratory rate and neural timing [9]. That technique en-
abled an easy computation of the asynchrony index (AI), a
metric previously reported to be an independent predictor
of longer MV and ICU stay [6].
Because dexmedetomidine is an α2-adrenoceptor agonist
that provides sedation and anxiolysis via receptors in the
locus coeruleus [10], as well as analgesia via receptors at the
spinal cord level, it is able to attenuate the stress response
without significant respiratory depression [11–15]. This
pharmacological profile may be of particular interest in pa-
tients receiving assisted MV because it may possibly reduce
the rate of patient-ventilator asynchronies directly generated
by the influence of sedatives on the output of the respiratory
centres, which can affect the respiratory drive and/or timing.
In two double-blind, prospective, randomised clinical
trials, researchers recently compared dexmedetomidine
with propofol and midazolam in mechanically ventilated
critically ill patients. Both studies showed that dexmede-
tomidine is an effective sedative agent compared with
propofol and midazolam, and that its use is associated
with easier communication with patients, better assess-
ment of pain, reduced delirium and decreased time to
extubation compared with propofol [16].
We hypothesized that dexmedetomidine may reduce
the incidence of patient-ventilator dyssynchronies com-
pared with propofol. To examine this hypothesis, we
conducted a multicentre, prospective, open-label, rando-
mised clinical trial, comparing dexmedetomidine against
standard sedation with propofol infusion.
Methods
Patients
Adult ICU patients who had failed one weaning trial were
recruited. For the purposes of this study, difficulty to wean
was determined by failure at a single adequate weaning
trial, according to a common weaning protocol based on
the progressive reduction of the pressure support (PS)
level and ending with a spontaneous breathing trial of 30
minutes at 7 cmH2O of pressure support ventilation
(PSV) and positive end-expiratory pressure (PEEP) of 5
cmH2O, using the following standard criteria [17]:
1. Respiratory rate >35 breaths/minute
2. Partial pressure of oxygen (PaO2) <65 mmHg with
fraction of inspired oxygen (FiO2) <0.5 or oxygen
saturation (SaO2) <90 %
3. Partial pressure of carbon dioxide (PaCO2) >50
mmHg or an increase in PaCO2 > 8 mmHg
4. pH <7.32 or decrease of ≥0.07 pH units
5. Evident respiratory distress (diaphoresis, accessory
muscle recruitment, thoracoabdominal paradox)
6. Heart rate (HR) >140 beats/minute or a sustained
increase or decrease in HR >20 %
7. Severe arrhythmias
8. Systolic arterial pressure <90 mmHg or >180 mmHg
9. Coma, agitation or anxiety.
Patients who had been intubated and mechanically
ventilated in the ICU for >24 h and who had received
propofol as the sole agent for continuous sedation (mini-
mum 12 h) with a target sedation level of +1 to −2 on
the Richmond Agitation-Sedation Scale (RASS) were in-
cluded in the study.
Patients who had already failed more than one weaning
trial were excluded. Other key exclusion criteria were as
follows:
1. Acute severe intracranial or spinal neurological
disorder
2. Uncompensated acute circulatory failure
3. Severe bradycardia
Study design and procedures
We conducted a phase IIIb, multicentre, prospective,
randomised, open-label, comparator-controlled study.
The ethics committees of the University of Turin and
the Catholic University of Rome approved the protocol,
and informed consent was obtained from all patients.
The protocol was recorded in the European Clinical
Trials Database (EudraCT 2011-001490-40).
Equipment
MV was applied using a Servo-i ventilator equipped with
NAVA software (Maquet Critical Care, Solna, Sweden).
EAdi was determined using a nasogastric feeding tube
with a multiple array of electrodes placed at its distal
end (EAdi catheter; Maquet Critical Care). Correct posi-
tioning of the EAdi catheter was ensured using a dedi-
cated function of the ventilator, as previously described
[18]. During the study, all patients were mechanically
ventilated in PSV mode (range 10–18 cmH2O) with a
PEEP of 5–8 cmH2O and an FiO2 ranging between 0.35
and 0.5. Attending physicians optimized the ventilator
settings according to a protocol based on clinical re-
sponse, blood gas values and ventilator tracings. The
level of PS was titrated to obtain a tidal volume of 6–8
ml/kg with active inspiration [9]. Servo-i default trigger
settings were used during the study period (inspiratory
level 5, corresponding to 50 % of the 2 L/minute bias
flow; expiratory 30 % of peak inspiratory flow); in cases
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of evident short cycling, the cycling off was optimized
according to the patient’s EAdi signal. FiO2 and PEEP
were maintained at the values in use prior to patient en-
rolment. Ventilator settings were kept as constant as
possible during the study.
Study protocol
Prior to randomisation, each centre enrolled three run-in
patients who were treated with dexmedetomidine so that
study staff could become familiar with the agent. Neural
and respiratory parameters were not collected from these
patients, who were included only in the safety analyses.
For the first 24 h after the start of the study treatment,
periodic measurements of EAdi, respiratory parameters
and arterial blood gases were assessed to compare the
effects of dexmedetomidine and propofol on ventilation.
During this period, 10-minute samples were taken at 0,
0.5, 1, 2, 6, 12, 18 and 24 h, and all breaths were ana-
lysed for evidence of asynchrony. For each patient, we
also measured the average peak EAdi (i.e., the maximum
level of EAdi generated by the diaphragm) and time of
synchrony (i.e., the time in which the mechanical inspir-
ation generated by the ventilator and diaphragmatic con-
traction were in phase) over 10 minutes of data
recording. For determination of the primary endpoint,
all of these 10-minute samples were added together to
create the AI. The AI is expressed as the percentage of
total breaths during the period of interest in which asyn-
chrony is identified. It has previously been analysed in
other trials [6, 7] and is expressed as follows:
AI ¼ number of asynchrony events=total respiratory rateð Þ  100;
where the total respiratory rate is obtained from the
EAdi tracings and the following asynchronies are consid-
ered in the computation of the AI: wasted effort,
double-triggering and auto-triggering.
At the end of the 24-h treatment period, a weaning at-
tempt was made. Further attempts were made at least
every 24 h until the patient was successfully extubated.
Secondary endpoints included maximum level of EAdi
per breath expressed in microvolts (peak EAdi), time of syn-
chrony, respiratory rate, arterial blood gas parameters, time
to extubation, duration of MV and duration of ICU stay.
The assigned study treatment was continued until suc-
cessful extubation, but for no longer than 14 days. Fol-
lowing withdrawal of sedation, patients were monitored
for 48 h and either contacted by telephone or assessed
at a visit 30 (±5) days after randomisation.
Drugs
After the index weaning failure, all patients required a
continuous infusion of sedatives due to anxiety generated
by respiratory distress and endotracheal tube intolerance.
Patients were randomised to receive either dexmedetomi-
dine (Orion Pharma, Espoo, Finland), or propofol (pur-
chased within the European Union) intravenously at rates
of 0.2–1.4 μg/kg/h and 0.3–4 mg/kg/h, respectively, to
maintain the RASS score within the range of +1 to −2.
The identity of study sedatives was not blinded to
caregivers.
During the course of the study, and especially during
the first 24 h, the investigators attempted to manage the
sedation of patients using the study drug only. Rescue
midazolam was used if needed; however, because it had
the potential to interfere with the study measurements,
participants were advised that it should be used as spar-
ingly as possible. Non-opioid drugs such as paracetamol
were preferred for controlling pain.
Statistical analysis
The primary efficacy variable, AI, was analysed using a
repeated-measures analysis of covariance (ANCOVA)
model with the study treatment group, centre and base-
line AI as between factors and time as the within factor.
Individual time points were compared between the study
treatment groups.
The secondary efficacy variables, which comprised other
neural and respiratory parameters, were analysed similarly
to the AI. For arterial blood gases, the mean change from
baseline between treatment groups was compared using
repeated-measures ANCOVA, where time was considered
as the within factor, treatment as the between factor and
baseline as the covariate. Time to extubation and duration
of MV were compared between treatment groups by ap-
plying the Kaplan-Meier method and Cox proportional
hazards regression, respectively.
All randomised subjects who received the study treat-
ment were used to evaluate the efficacy variables. Safety
data were evaluated using descriptive statistics for all
subjects who received the study medication.
The planned sample size of ten in each group had 80 %
power to detect a difference in means of 8.3 %, assuming
that the common standard deviation is 6.0, using a two-
group t test with a two-sided significance level of 0.05. In
response to evidence of a non-normal distribution, AI data
were transformed before the analysis using a two-
parameter version of the Box-Cox transformation.
Results
In total, 26 patients were enrolled, the first 6 of whom
were selected for run-in treatment. The other 20 pa-
tients (11 men, 9 women) were randomised to receive
either dexmedetomidine or propofol. The patients’ mean
(standard deviation [SD]) age was 68.8 (15.7) years
(range 39–88 years), and their mean (SD) weight was
77.2 (20.8) kg. All patients were white. The main reason
for admission to the ICU was medical (50 %), followed
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by surgical (35 %) and trauma (15 %). The main medical
reason for admission to the ICU was cardiac disorders
(ten patients). These predominantly included arrhythmia
(five patients in each group), chronic cardiac failure
(three in the dexmedetomidine group and one in the
propofol group) and myocardial ischaemia and infarction
(two in each group).
The median durations of study treatment were 31.5 h
(range 18–174 h) in the dexmedetomidine group and 47.9
h (range 22–113 h) in the propofol group. The average
doses were 0.46 μg/kg/h in the dexmedetomidine group
and 1.08 mg/kg/h in the propofol group. At 30-day
follow-up, three patients in the propofol group and four
patients in the dexmedetomidine group had died, and one
patient in the propofol group was lost to follow-up.
Efficacy
Primary endpoint
The mean AI was lower with dexmedetomidine than with
propofol from 2 h onwards, although the two groups dif-
fered significantly only at 12 h (2.68 % vs 9.10 %, p < 0.05)
(Fig. 1). No further statistical difference was observed at
18 and 24 h. Of note, in basal conditions, two patients per
group had an AI >10 %; at 6 h, two patients in the
propofol group and one in the dexmedetomidine group
had an AI >10 %; and at 12 and 24 h, four patients in the
propofol group and one in the dexmedetomidine group
had an AI >10 %.
Secondary endpoints
At similar levels of PSV and PEEP in both groups (PSV
12.4 ± 2.5 cmH2O vs 12.9 ± 2.4 cmH2O, respectively; p =
0.33; PEEP 5.4 ± 1 cmH2O vs 5.8 ± 0.9 cmH2O, respectively;
p = 0.17), there were no significant inter-group differences
during the first24 h in peak EAdi over time, time of syn-
chrony, tidal volume, minute volume, peak airway pressure,
ventilator respiratory rate, mean lactate, PaCO2, PaO2,
SaO2 and pH (Fig. 2).
There was some imbalance between the two groups
regarding peak EAdi at baseline, which persisted at the
end of 24 h, but there were no significant differences be-
tween the treatments (Fig. 3).
Time to extubation
The median times to extubation were 25.18 h (range 24.5–
118.7 h) in the dexmedetomidine group and 57.33 h (range
24.7–113.0 h) in the propofol group (hazard ratio [HR]
0.974, 95 % confidence interval [CI] 0.373–2.542, p =
0.958).
Duration of ICU stay
The median durations of ICU stay were 6.02 days (range
2.2–8.5 days) in the dexmedetomidine group and 10.06
days (range 5.0–24.8 days) in the propofol group (HR
0.843, 95 % CI 0.305–2.330, p = 0.742). Consequently, the
average cost of ICU stay was less in the dexmedetomidine
group than in the propofol group (€20,387 vs €29,010).
Episodes of oversedation
All patients remained within the target sedation range
(RASS score +1 to −2) during the entire study period,
with the exception of two subjects receiving propofol,
for whom the RASS score was less than −2 on at least
one occasion. There were no subjects with a RASS score
less than −2 in the dexmedetomidine group. Midazolam
(single 1-mg intravenous bolus) as a sedative was given
Fig. 1 Variation in asynchrony index (AI) with dexmedetomidine and propofol
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to two patients in the dexmedetomidine group and to
one in the propofol group. For pain control, a fen-
tanyl bolus dose of 50 μg was used in two patients in
the dexmedetomidine group and in three in the pro-
pofol group.
Daily weaning trial outcome and reasons for failure
On day 2, nine patients were successfully extubated
(six in the dexmedetomidine group and three in the
propofol group). Common causes of failure of the
weaning trial in both groups are summarized in
Fig. 2 Variation in respiratory parameters with dexmedetomidine and propofol
Fig. 3 Variation in peak electrical activity of the diaphragm (EAdi) with dexmedetomidine and propofol
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Table 1. No patient required reintubation in the first
24 h after extubation.
Adverse events
The only treatment-related adverse event observed dur-
ing the study in the dexmedetomidine group was brady-
cardia in one patient. In the propofol group, one
individual prematurely discontinued the study due to de-
creased cough efficiency and increased bronchial secre-
tion, and one died as a result of sudden cardiac arrest
(Table 2).
Discussion
This study produced indications that, after optimization
of ventilator settings according to clinical response,
blood gases and ventilator tracings for the same level of
sedation, the AI was lower with dexmedetomidine than
with propofol. The difference was small; however, it was
statistically significant only at the 12-h time point and
emerged from a small patient sample characterized by a
high degree of variation and a non-normal distribution.
As such, our findings regarding AI should be regarded
as suggestive rather than conclusive. Additional clinical
studies with larger populations and/or datasets are
needed to develop our observations.
Sedatives influence the output of the respiratory cen-
tres by affecting the respiratory drive and/or timing. As-
sessment of EAdi allowed Vaschetto et al. [9] to show
that, at doses determining deep sedation, propofol re-
duced neural drive and effort while not significantly af-
fecting respiratory timing and therefore produced a
significant deterioration in patient-ventilator synchrony.
Dexmedetomidine, an α2-adrenoceptor agonist, does not
induce respiratory depression and has not been associated
with any effect on patient respiratory activity [12–15].
Moreover, recent studies [16, 19–21] have demonstrated
that dexmedetomidine, by virtue of its pharmacodynamic
properties, appears to shorten the duration of MV com-
pared with midazolam and the time to extubation com-
pared with both midazolam and propofol.
Optimized interaction with the mechanical ventilator
is an important aspect of assisted ventilatory support.
Poor patient-ventilator interaction causes discomfort
and dyspnoea [22–26], increases the need for sedative
and paralytic agents [27], prolongs MV duration and
ICU length of stay [6, 28, 29], and increases both the
likelihood of respiratory muscle injury [30, 31] and the
need for tracheostomy [6].
Several groups of authors have directly analysed the
clinical effects of a high rate of asynchronies during
assisted MV. Thille et al. [6] showed that ineffective ex-
piratory efforts and double-triggering accounted for >98 %
of all asynchronies and that an AI >10 % was associated
with a longer duration of MV, whereas de Wit et al. [28]
found that an ineffective triggering index >10 % was an in-
dependent predictor of longer MV duration and ICU stay.
Very recently, Blanch et al. [32], in a study in which 50
patients were evaluated continuously for >7027 h using
specific automatic software for detecting asynchronies,
partly confirmed these data, showing that an AI >10 %
was associated with a trend towards a longer duration of
MV and significantly higher ICU and hospital mortality.
In more detail, ICU mortality was 14 % vs 67 % (p < 0.01)
and hospital mortality was 23 % vs 67 % (p = 0.04) in a dir-
ect comparison of patients with an AI < 10 % with patients
with an AI >10 %.
Strengths of the present study include the use of ob-
jective variables to assess the primary endpoint (AI) and
that the two regimens were compared at similar sedation
levels and at similar levels of ventilator assistance and
PEEP. Some limitations must be taken into account,
however. First, only 20 patients were enrolled, which
represents too small a sample to establish statistically ro-
bust and conclusive findings. Second, staff treating the
patients were not blinded regarding the sedative admin-
istered. However, to limit the influence of this drawback,
the researchers who analysed the patients’ respiration
tracings were blinded regarding the choice of sedative.
Conclusions
Our data indicate that when sedation with propofol or
dexmedetomidine was directly compared at similar levels
of sedation (RASS score −1 to +2), and at similar levels of
PSV and PEEP in a group of patients for whom the first
weaning trial had failed and were therefore at risk of an in-
creased rate of patient-ventilator asynchrony, there were
no significant between-group differences in terms of peak
EAdi, minute volume, ventilator respiratory rate, arterial
blood gases, rate of adverse events, length of stay in the
ICU or time of extubation. Conversely, the AI was lower
with dexmedetomidine than with propofol from 2 h on-
wards, although the two groups differed significantly only
at 12 h. The results of our study suggest that, after
optimization of ventilator settings, sedation with dexme-
detomidine could offer some advantages in terms of
patient-ventilator synchrony, but additional clinical studies
Table 1 Common causes of failure of weaning trial on day 2
Cause of failure Number of patients
Dexmedetomidine Propofol
Respiratory rate >35 breaths/minute 2 4
PaO2 <65 mmHg with FiO2 <0.5 or SaO2
<90 %
1 4
Evident respiratory distress 2 3
Coma, agitation or anxiety 2 3
FiO2 fraction of inspired oxygen, PaO2 partial pressure of oxygen, SaO2
oxygen saturation
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with larger populations are needed to confirm this
postulation.
Key messages
 When sedation with propofol or dexmedetomidine
was compared at similar Richmond Agitation-
Sedation Scale scores in patients for whom the first
weaning trial had failed, the asynchrony index was
lower with dexmedetomidine, and this difference
was statistically significant at 12 h.
 These results suggest that sedation with
dexmedetomidine could offer some advantages in
terms of patient-ventilator synchrony.
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